ArticleScandinavian journal of trauma, resuscitation and emergency medicine2013
Hydroxyethyl starch - the importance of being earnest.
Article in Scandinavian journal of trauma, resuscitation and emergency medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Sources of Heterogeneity in Trials Reporting Hydroxyethyl Starch 130/0.4 or 0.42 Associated Excess Mortality in Septic Patients: A Systematic Review and Meta-regression.Chinese medical journal · 2015Pooled it
- [The PHOENICS study: current evidence on the use of hydroxyethyl starch].Die Anaesthesiologie · 2026Article
- Renal Safety of Hydroxyethyl starch 130/0.42 After Cardiac Surgery: A Retrospective Cohort Analysis.Drug safety · 2021Article
- A Prospective Observational Study of Rational Fluid Therapy in Asian Intensive Care Units: Another Puzzle Piece in Fluid Therapy.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2020Article
- Understanding the Harms of HES: A Review of the Evidence to Date.Turkish journal of anaesthesiology and reanimation · 2019Review
- Pragmatic clinical trials in the context of regulation of medicines.Upsala journal of medical sciences · 2019Article
- Starch Wars-New Episodes of the Saga. Changes in Regulations on Hydroxyethyl Starch in the European Union.Frontiers in veterinary science · 2018Review
- Effect of tetrastarch (hydroxyethyl starch 130/0.4) on plasma creatinine concentration in cats: a retrospective analysis (2010-2015).Journal of feline medicine and surgery · 2017Article
- Strategies for Intravenous Fluid Resuscitation in Trauma Patients.World journal of surgery · 2017Review
- Current Trends in Volume Replacement Therapy and the Use of Synthetic Colloids in Small Animals-An Internet-Based Survey (2016).Frontiers in veterinary science · 2017Article
- Use of perioperative hydroxyethyl starch 6% and albumin 5% in elective joint arthroplasty and association with adverse outcomes: a retrospective population based analysis.BMJ (Clinical research ed.) · 2015Article
- Induced Hypothermia Does Not Harm Hemodynamics after Polytrauma: A Porcine Model.Mediators of inflammation · 2015Article
- [Fluid resuscitation in hemorrhage].Der Anaesthesist · 2014Review
- Hydroxyeyhyl starch: Controversies revisited.Journal of anaesthesiology, clinical pharmacology · 2014Review
- [Rational fluid and volume replacement therapy: wishful dream or realistic future option].Der Anaesthesist · 2014Article
- Reporting bias in trials of volume resuscitation with hydroxyethyl starch.Wiener klinische Wochenschrift · 2014Review
- Twisting and ignoring facts on hydroxyethyl starch is not very helpful.Scandinavian journal of trauma, resuscitation and emergency medicine · 2013Article
- Debate on HES safety is important, but must be based on facts.Scandinavian journal of trauma, resuscitation and emergency medicine · 2013Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite ongoing controversial expert discussions the European Medicines Agency (EMA) recently recommended to suspend marketing authorisations for hydroxyethyl starch. This comment critically evaluates the line of arguments. Basically, the only indication for a colloid is intravascular hypovolemia. Crystalloid use appears reasonable to compensate ongoing extracellular losses beyond. In the hemodynamically instable patient this leads to the distinction between an initial resuscitation phase where colloids might be indicated and a crystalloidal maintenance phase thereafter. It is important to bear this in mind when reevaluating the studies the EMA referred to in the context of its recent decision: i) VISEP compared ringer's lactate to 10% HES 200/0.5 in septic patients and found an increased incidence of renal failure in HES receivers. Unfortunately, study treatment was started only after initial stabilization with HES, randomizing hemodynamically stable patients into a rational (crystalloids) and an irrational (high dose starch until ICU discharge) maintenance treatment. ii) 6S compared ringer's acetate to 6% HES 130/0.42 for fluid resuscitation in septic patients and found an increased need of renal replacement therapy and a higher mortality in the HES group. However, patients of both groups were again randomized only after initial stabilization with colloids, the actual comparison was, therefore, again rational vs. irrational. Beyond that, the documentation is partly fragmentary, leaving many important questions around the fate of the patients unanswered. iii) CHEST randomized ICU patients to receive saline or 6% HES 130/0.4 for fluid resuscitation. Actually, despite partly discussed in a different way, this trial showed no relevant differences in outcome. In all, two studies showed what happens to septic patients if starches are used in a way we do not observe in daily practice. The third one actually proves their safety. The benefit of perioperative goal-directed preload optimization using starches is unquestioned. Taking these informations into account, the recommendation of the EMA starches to be generally dangerous remains mysterious and incomprehensible. An authority being able to dictate behavior should stand clear from oppressively ending a worldwide expert discussion and step back into the role of the observer until science achieves an agreement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.